✦ LIBER ✦

Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial

Book ID: 117783988
Publisher: The Lancet
Year: 2006
Tongue: English
Weight: 400 KB
Volume: 7
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(06)70767-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effect of anastrozole and tamoxifen as a

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

✍ Jack Cuzick; Ivana Sestak; Michael Baum; Aman Buzdar; Anthony Howell; Mitch Dows 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 395 KB

Effect of anastrozole and tamoxifen as a

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 289 KB

Anastrozole alone or in combination with

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer : Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses

✍ The ATAC (Arimidex; Tamoxifen Alone or in Combination) Trialists' Group 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB 👁 2 views

## Abstract ## BACKGROUND The first analysis of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial (median follow‐up, 33 months) demonstrated that in adjuvant endocrine therapy for postmenopausal patients with early‐stage breast cancer, anastrozole was superior to tamoxifen in terms of d

PCN119 COST EFFECTIVENESS ANALYSIS OF AN

PCN119 COST EFFECTIVENESS ANALYSIS OF ANASTROZOLE VERSUS TAMOXIFEN IN ADJUVANT THERAPY FOR EARLY STAGE BREAST CANCER BASED ON THE 100-MONTH ANALYSIS OF THE ATAC TRIAL FROM A GERMAN PERSPECTIVE

✍ N Kreif; Á Benedict; MP Lux; A Wöckel; MB Klevesath 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

Cost-effectiveness analysis of anastrozo

Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial

✍ Gershon Y. Locker; Robert Mansel; David Cella; Deborah Dobrez; Sonja Sorensen; S 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 267 KB

CN3 HEALTH ECONOMIC EVALUATION BASED ON

CN3 HEALTH ECONOMIC EVALUATION BASED ON THE 5-YEAR COMPLETED TREATMENT ANALYSIS OF THE ATAC TRIAL COMPARING ANASTROZOLE VERSUS TAMOXIFEN IN ADJUVANT TREATMENT OF POSTMENOPAUSAL HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER

✍ K Moeremans; L Annemans 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB